Promore Pharma
9.11.2021 12:02:15 CET | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / November 9, 2021 / Promore Pharma (STO:PROMO)(FRA:8T0)
Stockholm, November 9, 2021 - Promore Pharma AB, a Swedish biopharmaceutical company that develops peptide-based drug candidates, announced today that the company has received approval from the Medical Products Agency and the Swedish Ethics Review Authority to begin a clinical phase II trial of ensereptide for skin scarring prevention.
The company announces today that a clinical trial permit has been obtained from the Medical Products Agency in Sweden and that the company's application for approval from the Ethical Review Authority has also been granted. PHSU05 is a Phase II pilot study with the aim of being able to evaluate ensereptide regarding (i) local tolerance, (ii) the application process of the experimental drug, and (iii) preliminary effect on scar prevention after experimentally induced wounds in healthy volunteers. Planned study start is Q1 2022 and results from the study are expected in the winter of 2022/2023.
"This is an important step in our long-term goal of developing a new product concept to prevent the occurrence of post-surgical and post-traumatic scars on the skin. These approvals are fully aligned with our operational plan in the ensereptide project ", says Jonas Ekblom, CEO of Promore Pharma.
Bolagets ensereptide-program fokuseras för närvarande på prevention av ärr i huden i samband med kirurgi eller trauma, men det finns även potential att utveckla produkten för andra medicinska applikationer som prevention av sammanväxning efter hand- och ryggradskirurgi.
The company's ensereptide program is currently focused on the prevention of scarring of the skin in connection with surgery or trauma, but there is also potential to develop the product for other medical applications such as prevention of adhesions after surgeries in the hand or spine.
Scars develop after virtually all types of damage to the skin. Although scars can often be considered trivial, a large proportion of them can be disfiguring and aesthetically pleasing, and they can also create itching, stiffness, sleep problems, anxiety, depression and negatively affect activities of daily life.
The world market for products for the treatment of scars, including laser treatment, scar revision and self-care products, amounts to USD 25 billion with an annual growth of about 10%, according to independent estimates. Today, there are no prescription drugs for wound prevention.
For additional information, please contact
Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com
Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.
This information is information that Promore Pharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-11-09 11:38 CET.
Attachments
Promore Pharma receives permits to start a phase II clinical trial regarding scar prevention
SOURCE: Promore Pharma
View source version on accesswire.com:
https://www.accesswire.com/671849/Promore-Pharma-Receives-Permits-to-Start-a-Phase-II-Clinical-Trial-Regarding-Scar-Prevention
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Karbon-X Reports Increased Engagement as Canadian Facilities Reassess Compliance Exposure Ahead of Carbon Deadlines6.5.2026 15:15:00 CEST | Press release
170% year-over-year increase in traded volumes across TIER and BC OBPS within Karbon-X's trading activity reflects accelerated procurement activity as regulated entities enter the execution phase of the 2026 compliance cycle. CALGARY, AB / ACCESS Newswire / May 6, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions provider operating across compliance and voluntary carbon markets, today reported increased engagement from regulated facilities across Canada as organizations reassess their compliance position ahead of upcoming reporting and credit surrender deadlines. This includes a 170% increase in traded volumes across TIER and BC OBPS markets within Karbon-X's trading activity compared to the prior year, reflecting increased participation as facilities move into active procurement and execution phases ahead of submission timelines. As the current compliance cycle progresses across Alberta's Technology Innovation and Emissions Red
Global Sports Brand U.S. Polo Assn. Delivers Record $2.7 Billion in Retail Sales for 2025, Targets $4 Billion and 1,500 U.S. Polo Assn. Stores6.5.2026 13:00:00 CEST | Press release
WEST PALM BEACH, FL / ACCESS Newswire / May 6, 2026 / USPA Global, the company that manages U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), today announced that the global sports brand has delivered a record $2.7 billion in worldwide retail sales in 2025, reflecting strong momentum across global markets, channels, and product categories. U.S. Polo Assn. is advancing toward a long‑term goal of $4 billion in global retail sales and 1,500 branded stores worldwide. Record Growth and Global Momentum U.S. Polo Assn.'s 2025 record-breaking performance was driven by continued expansion across both established and emerging markets. North America, the brand's largest region, delivered steady gains, while strong momentum continued across India, the Middle East, Western Europe, and Latin America. Emerging regions, including Asia Pacific and Eastern Europe, also contributed to meaningful growth for the global multi-billion-dollar brand. India remains the bra
Case IQ Advances Its Leadership Position in AI For Investigations with Playbooks6.5.2026 10:00:00 CEST | Press release
Playbooks is a new way to guide AI toward investigative outcomes that ethics, compliance, and HR teams across the EU can trust. LONDON, GB / ACCESS Newswire / May 6, 2026 / Case IQ, the leading provider of end-to-end compliance and risk management solutions for ethics, compliance and HR teams, today announced Playbooks, a new enhancement to Clairia, its AI assistant purpose-built for investigators. Case IQ continues to raise the bar for AI in investigations with Playbooks, which brings greater consistency, control, and confidence to AI-assisted case management. Playbooks enable organizations to shape how AI supports investigators based on their own standards, policies, and operational needs. Organizations feel pressure to adopt AI for investigations, making it difficult to govern, especially while navigating different regulations and standards across EU regions/countries. It's no surprise, as AI adoption is rising: according to our recent investigative benchmark report, which surveyed
Transoft Solutions Acquires CADaptor Solutions6.5.2026 08:00:00 CEST | Press release
Transoft Solutions Expands Temporary Traffic Management Portfolio With Latest Acquisition VANCOUVER, BC / ACCESS Newswire / May 6, 2026 / Transoft Solutions, a global leader in transportation engineering, analysis, and operations software, is pleased to announce that it has acquired CADaptor Solutions Ltd, developers of temporary traffic management software. CADaptor Solutions is based out of Huddersfield, UK and was established over 30 years ago. Their CONE Software solution is used widely in the United Kingdom within the Traffic Management industry to aid in the preparation of temporary traffic control diagrams, route diversion and event management schemes. CONE covers all aspects of temporary traffic management design from simple pedestrian footways through to complex multi-lane highway closures and contra-flows. It is used by wide variety of traffic planning related professionals including Highways Agencies, Utility Companies, Local Government, Traffic Management Companies, Civil E
Lawline Exits Beta and Launches Full AI Legal Platform for Businesses and Individuals5.5.2026 15:00:00 CEST | Press release
Sweden's most visited legal platform, recognised among the Nordics' top 9 AI legal startups alongside Legora and others, moves out of beta after surpassing 7,000 registered users, expanding its offering for companies, organisations, and individuals. STOCKHOLM, SE / ACCESS Newswire / May 5, 2026 / Lawline, Sweden's most visited legal platform, today announced the official launch of its AI-driven legal platform, marking its transition out of beta. The launch introduces a significantly expanded product offering aimed at businesses, organisations, and individuals seeking accessible, reliable legal support in everyday decision-making. Lawline AI was first released in beta in February 2026 and has since attracted more than 7,000 registered users. With today's full launch, Lawline introduces a broader suite of capabilities designed to bring legal support closer to where decisions are actually made. "Legal support has traditionally been something you access after the fact, often when problems
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom